Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Nov;148(11):1324-5.
doi: 10.1001/archdermatol.2012.2354.

Initial assessment of tumor regrowth after vismodegib in advanced Basal cell carcinoma

Anne Lynn S Chang, Anthony E Oro

Initial assessment of tumor regrowth after vismodegib in advanced Basal cell carcinoma

Anne Lynn S Chang et al. Arch Dermatol. 2012 Nov.
No abstract available

PubMed Disclaimer

Figures

Figure
Figure
A 67-year-old man with tumor regrowth. A, Nodular basal cell carcinoma (BCC) on right forehead prior to treatment. B, The BCC responded to vismodegib and healed, leaving a depressed scar shown here after 7 months of treatment. C, After 12 months of continuous vismodegib therapy, 2 biopsy-proven BCCs developed within the boundaries of the prior tumor, one a superficial and nodular subtype (upper arrow), and the other a nodular subtype (lower arrow).
See this image and copyright information in PMC

References

    1. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009;361(12):1164–1172. - PubMed
    1. LoRusso PM, Rudin CM, Reddy JC, et al. Phase 1 trial of hedgehog pathway inhibitor vismodegib (GDC0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011;17(8):2502–2511. - PMC - PubMed
    1. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171–2179. - PMC - PubMed
    1. Metcalfe C, de Sauvage FJ. Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists. Cancer Res. 2011;71(15):5057–5061. - PubMed
    1. Dijkgraaf GJ, Alicke B, Weinmann L, et al. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res. 2011;71(2):435–444. - PubMed